HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Failure of alphacalcidol (1alpha-hydroxyvitamin D3) in treating nutritional rickets and the biochemical response to ergocalciferol.

Abstract
It has been previously documented that alphacalcidol (1alpha-hydroxyvitamin D3) is inefficient in healing rickets, partly because it results in a suboptimal rise in 1,25-dihydroxyvitamin D (1,25-(OH)2D) and partly because it fails to replenish the store of 25-hydroxyvitamin D (25-OHD). However, very few studies have actually documented this outcome. The aim was to document biochemically the response to alphacalcidol and subsequently the change in response to ergocalciferol. This study was conducted at our institution from January 2005 till December 2008. We included all patients referred to our clinic with active rickets after a failed course of alphacalcidol. At baseline the median (IQR) for PTH l7.1 (4.5-35.3) pmol/L, 25-OHD 29.0 (18-66.2) nmol/L, 1,25-(OH)2D 205 (158.2-311.2) pmol/L and ALP 676 (462.5-1101.7) IU/L. After 3 months treatment with ergocalciferol the concentrations changed markedly with biochemical healing: PTH 4.5 (3.9-7.5), 25-OHD 143.5 (101.5-206.5), 1,25-(OH)(2)D 277 (221.0-572.7), ALP 369 (302.2-438.0). The results confirm the biochemical and physiological basis for using ergocalciferol (or cholecalciferol) in nutritional rickets. Unfortunately these forms are not readily available in many geographic areas. This supply problem together with marketing strategies forces physicians to make an incorrect choice of medication. Treatment with ergocalciferol was either with intramuscular stosstherapy or drops for 3 months. The former ensures compliance and is associated with higher 25-OHD and 1,25-(OH)2D concentrations.
AuthorsJaishen Rajah, Laila Abdel-Wareth, Afrozul Haq
JournalThe Journal of steroid biochemistry and molecular biology (J Steroid Biochem Mol Biol) Vol. 121 Issue 1-2 Pg. 273-6 (Jul 2010) ISSN: 1879-1220 [Electronic] England
PMID20398760 (Publication Type: Journal Article)
CopyrightCopyright (c) 2010 Elsevier Ltd. All rights reserved.
Chemical References
  • Bone Density Conservation Agents
  • Ergocalciferols
  • Hydroxycholecalciferols
  • Vitamin D
  • alfacalcidol
Topics
  • Bone Density Conservation Agents (therapeutic use)
  • Child, Preschool
  • Dietary Supplements
  • Ergocalciferols (metabolism, pharmacology)
  • Female
  • Humans
  • Hydroxycholecalciferols (therapeutic use)
  • Infant
  • Male
  • Nutrition Disorders (metabolism)
  • Pediatrics (methods)
  • Retrospective Studies
  • Rickets (drug therapy, metabolism)
  • Treatment Outcome
  • Vitamin D (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: